Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Study Information
Alliance Study ID: A091104
NCT Study ID (ClinicalTrials.gov): NCT01604772
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Thyroid & Neuroendocrine / Endocrine Cancers
Alliance Study Chair: Alan Ho
Status: COMPLETED
Study Description
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer). Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information